Published in Glycoconj J on October 09, 2009
Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol (2012) 2.65
Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv (2010) 1.08
Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res (2012) 0.92
Liposomes and nanotechnology in drug development: focus on oncotargets. Int J Nanomedicine (2012) 0.83
Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3. Front Microbiol (2013) 0.83
Oligomannose-coated liposome as a novel adjuvant for the induction of cellular immune responses to control disease status. Biomed Res Int (2013) 0.80
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell (2015) 0.78
SIGNR1 ligation on murine peritoneal macrophages induces IL-12 production through NFkappaB activation. Glycoconj J (2010) 0.77
The mucosal adjuvant potential of cross-linked dextran microspheres as dry powder. Iran J Basic Med Sci (2012) 0.75
Nanoparticle-allergen complexes for allergen immunotherapy. Int J Nanomedicine (2017) 0.75
Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature (1988) 5.56
Myeloid C-type lectins in innate immunity. Nat Immunol (2006) 3.41
M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbial transepithelial migration. J Infect Dis (1986) 3.32
Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med (2004) 2.13
Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today (1999) 1.74
Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol Today (1999) 1.72
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology (1992) 1.68
Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun (2000) 1.35
Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine (1998) 1.35
New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol (2003) 1.34
Immune effects and mechanisms of action of CpG motifs. Vaccine (2000) 1.20
A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res (2006) 1.04
Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun (1999) 1.03
CpG DNA as mucosal adjuvant. Vaccine (1999) 0.96
Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect Immun (1998) 0.94
Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine (2002) 0.90
Interferon-gamma induces polymeric immunoglobulin receptor mRNA in human intestinal epithelial cells by a protein synthesis dependent mechanism. Mol Immunol (1993) 0.90
Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett (2008) 0.88
Novel vaccination strategies for the control of mucosal infection. Vaccine (1993) 0.87
Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. J Immunol (1992) 0.87
Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett (1998) 0.85
Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. J Control Release (2008) 0.85
Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine (2002) 0.84
Cytokine regulation of the mucosal immune system: in vivo stimulation by interferon-gamma of secretory component and immunoglobulin A in uterine secretions and proliferation of lymphocytes from spleen. Endocrinology (1991) 0.83
Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine (2002) 0.83
Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunol (2007) 0.83
Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol Lett (2005) 0.82
Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages. Glycobiology (2008) 0.81
Preferential production of IL-12 by peritoneal macrophages activated by liposomes prepared from neoglycolipids containing oligomannose residues. Cytokine (2007) 0.81
Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system. J Immunol (2001) 0.80
Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol (2006) 0.79
Development of a novel oligomannose-coated liposome-based anticancer drug-delivery system for intraperitoneal cancer. Curr Opin Mol Ther (2007) 0.78
Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin-producing Escherichia coli to Caco-2 cells by oral immunization with liposomes. Lett Appl Microbiol (2003) 0.77
Long-term persistence of cellular immunity to Oka vaccine virus induced by pernasal co-administration with Escherichia coli enterotoxin in mice. Vaccine (2001) 0.76
A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res (2006) 1.04
Origin of the classical complement pathway: Lamprey orthologue of mammalian C1q acts as a lectin. Proc Natl Acad Sci U S A (2004) 1.03
Novel role of the Ras cascade in memory B cell response. Immunity (2005) 0.95
Neospora caninum: application of apical membrane antigen 1 encapsulated in the oligomannose-coated liposomes for reduction of offspring mortality from infection in BALB/c mice. Exp Parasitol (2010) 0.89
Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorg Med Chem (2003) 0.89
Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett (2008) 0.88
Genetic diversity of Theileria orientalis in tick vectors detected in Hokkaido and Okinawa, Japan. Infect Genet Evol (2012) 0.87
Immunization with oligomannose-coated liposome-entrapped dense granule protein 7 protects dams and offspring from Neospora caninum infection in mice. Clin Vaccine Immunol (2009) 0.84
Cross-linking of SIGNR1 activates JNK and induces TNF-alpha production in RAW264.7 cells that express SIGNR1. Biochem Biophys Res Commun (2009) 0.83
Developmental changes in glycolipids and synchronized expression of nutrient transporters in the mouse small intestine. J Nutr Biochem (2009) 0.82
Structural studies on IgG oligosaccharides of patients with primary Sjögren's syndrome. Glycoconj J (2002) 0.82
Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine. Vaccine (2007) 0.82
Preferential production of IL-12 by peritoneal macrophages activated by liposomes prepared from neoglycolipids containing oligomannose residues. Cytokine (2007) 0.81
Histochemical expression of sialoglycoconjugates in carcinoma of the papilla of Vater. Hepatogastroenterology (2005) 0.81
Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages. Glycobiology (2008) 0.81
Oligomannose-coated liposome-entrapped dense granule protein 7 induces protective immune response to Neospora caninum in cattle. Vaccine (2013) 0.81
Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 1. A new strategy for generation of anti-carbohydrate antibodies. Biochemistry (2007) 0.81
Synthesis of a mimic for the heterogeneous surface of core 2 sialoglycan-linked glycoprotein. Org Lett (2004) 0.80
Anti-allergic potential of oligomannose-coated liposome-entrapped Cry j 1 as immunotherapy for Japanese cedar pollinosis in mice. Int Immunopharmacol (2010) 0.79
Binding of rainbow trout sperm to egg is mediated by strong carbohydrate-to-carbohydrate interaction between (KDN)GM3 (deaminated neuraminyl ganglioside) and Gg3-like epitope. Proc Natl Acad Sci U S A (2002) 0.79
Preferences for uptake of carbohydrate-coated liposomes by C-type lectin receptors as antigen-uptake receptors. Glycoconj J (2012) 0.78
Development of a novel oligomannose-coated liposome-based anticancer drug-delivery system for intraperitoneal cancer. Curr Opin Mol Ther (2007) 0.78
Contribution of complement component C3 and complement receptor type 3 to carbohydrate-dependent uptake of oligomannose-coated liposomes by peritoneal macrophages. J Biochem (2008) 0.78
SIGNR1 ligation on murine peritoneal macrophages induces IL-12 production through NFkappaB activation. Glycoconj J (2010) 0.77
Targeting with oligomannose-coated liposomes promotes maturation and splenic trafficking of dendritic cells in the peritoneal cavity. Int Immunopharmacol (2010) 0.77
A cholesterol-independent membrane microdomain serves as a functional counter-receptor for E-selectin at the Colo201 cell surface and initiates signalling on E-selectin binding. J Biochem (2007) 0.77
Regional expression of prosaposin in the wild-type and saposin D-deficient mouse brain detected by an anti-mouse prosaposin-specific antibody. Proc Jpn Acad Ser B Phys Biol Sci (2009) 0.76
Chemoenzymatic synthesis of a MUC1 glycopeptide carrying non-natural sialyl TF-beta O-glycan. Biosci Biotechnol Biochem (2006) 0.76
Level of galactosylation determines cryoglobulin activity of murine IgG3 monoclonal rheumatoid factor. Blood (2002) 0.76
Structural alterations in outer arms of IgG oligosaccharides in patients with Werner syndrome. Exp Gerontol (2007) 0.76
Oligomannose-coated liposomes activate ERK via Src kinases and PI3K/Akt in J774A.1 cells. Biochem Biophys Res Commun (2008) 0.76
Effective stimulation of invariant natural killer T cells by oligomannose-coated liposomes. Int Immunopharmacol (2013) 0.76
Plasmodium berghei circumsporozoite protein encapsulated in oligomannose-coated liposomes confers protection against sporozoite infection in mice. Malar J (2014) 0.75
High-performance thin-layer chromatography/mass spectrometry for rapid analysis of neutral glycosphingolipids. J AOAC Int (2008) 0.75
[Development of rheumatoid arthritis and abnormal IgG galactosylation]. Seikagaku (2002) 0.75
Efficacy of dipalmitoylphosphatidylcholine liposome against African trypanosomes. J Parasitol (2006) 0.75
Decabromodiphenyl Ether (DecaBDE) in Electrical and Electronic Equipment in Japan: Stock, Emission, and Substitution Evaluation. Environ Sci Technol (2017) 0.75